{"filings":[{"id":93025,"accession_number":"0001493152-26-018489","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SRx Health subsidiary invests >10% of investable capital in AI/space SPV","event_type":"other_material","confidence":"high","bullets":["Halo, Purely for Pets invests >10% of investable capital in Astro Investment XVII, an Astro Capital affiliate SPV.","Investment targets convergence of artificial intelligence and space technology sectors.","SRx is pursuing a definitive merger agreement with EMJ Crypto Technologies (EMJX).","EMJX CEO Eric Jackson highlights long-term value for shareholders from the investment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93024,"accession_number":"0001493152-26-017736","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SRx Health Solutions and EMJX Update Merger Progress, Report Treasury Returns","event_type":"m_and_a","confidence":"high","bullets":["Deployed $18M into Gen2 digital-asset treasury hedging strategy, March 2026 return of 5.69% vs S&P 500 decline of 4.98%.","Through mid-April, achieved approximate gains of 3.5% in hedging pool and 8% in long treasury holdings.","Filed Form S-4 registration statement with SEC for proposed merger with EMJ Crypto Technologies.","Company acquired shares of Compass Inc. in open market and increased investment in Opendoor Technologies Inc.","Eric M. Jackson, founder of EMJX, to become officer of EMJC subsidiary following merger closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104314,"accession_number":"0001493152-26-010911","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"SRx Health Solutions raises up to $8.0M via Series B preferred and warrants; initial close $4.528M","event_type":"other_material","confidence":"high","bullets":["Securities Purchase Agreement for up to 10,000 Series B shares ($1,000 stated value) and warrants at $0.3182 exercise price.","Initial closing of 5,660 Series B shares and 22,237,666 warrants for gross proceeds of ~$4.528M.","Warrants expire 3 years from exercisability; exercise price subject to adjustment after stockholder approval.","Company optional redemption at 125% of greater of stated value or market price; conversion price fixed at $0.3182."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104313,"accession_number":"0001493152-26-008656","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"SRx Health enters waiver for new Series B preferred stock offering","event_type":"other_material","confidence":"high","bullets":["Existing investors waive participation rights and consent to Series B Preferred Stock ranking pari passu with Series A.","New offering of Series B Preferred Stock and related warrants planned under a new securities purchase agreement.","Waiver relates to prior July 2025 note financing and October 2025 Series A financing agreements.","Company must file Form 8-K disclosing material non-public information by next business day.","Effective date of waiver is upon receipt of identical agreements from other holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104312,"accession_number":"0001493152-26-007565","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"SRx Health Solutions receives NYSE American warning letter over 7.5M share issuance without approval","event_type":"regulatory","confidence":"high","bullets":["NYSE American issued public warning letter on Feb 18, 2026 citing violations of Sections 301 and 713.","Company failed to file listing application and obtain shareholder approval for issuance of approx. 7.5 million shares upon conversion of Series A Preferred Stock.","Company had obtained stockholder approval by written consent on Oct 8, 2025, but NYSE deemed it deficient under internal guidance.","All preferred shares have been converted or redeemed as of report date; no preferred shares outstanding.","Company filed Form 8-K and press release on Feb 20, 2026 disclosing the warning letter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104311,"accession_number":"0001493152-26-006259","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"SRx Health redeems Series A Preferred for $21.8M, cancels ~125M common shares","event_type":"other_material","confidence":"high","bullets":["Redeemed 17,418 Series A Preferred shares at ~$21.77M; all outstanding shares eliminated.","Preferred represented ~125M common shares on as-converted basis, now cancelled, reducing dilution.","Prior private placement on Oct 31, 2025 issued 19,035 shares for $15.23M in proceeds.","Board member cites improved balance sheet flexibility for M&A or capital returns.","Company expects to file Q1 FY2026 Form 10-Q on Feb 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104310,"accession_number":"0001493152-26-000926","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"NYSE American accepts SRx Health's compliance plan; listing extended to July 14, 2026","event_type":"regulatory","confidence":"high","bullets":["NYSE accepted plan to regain compliance with Sections 1003(a)(i) and (ii) of the NYSE American Company Guide.","As of June 30, 2025, stockholders' equity was negative $45.9 million, triggering the listing deficiency.","Company will provide quarterly updates to NYSE during the Plan Period through July 14, 2026.","Previously notified of deficiency on October 14, 2025; plan acceptance avoids immediate delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120609,"accession_number":"0001493152-25-028965","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SRx Health shareholders OK name change to EMJX, EMJ Crypto acquisition","event_type":"other_material","confidence":"high","bullets":["Stockholders approved name change to EMJX, Inc. and ticker to EMJX, conditioned on closing of transaction.","Approved issuance of shares (≥20% of outstanding) at below market value to acquire EMJ Crypto Technologies and IP asset (AI algorithm for crypto trading).","Eric M. Jackson appointed CEO and Chairman effective upon closing of the transaction.","Elected directors: Simon Conway, Michael Young, Joshua A. Epstein, Sammy Dorf for term until 2026 annual meeting.","Also approved increase in 2019 Incentive Award Plan to 10% of outstanding shares (min 3,432,915) and ratification of Davidson & Company LLP as auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120608,"accession_number":"0001493152-25-027898","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"SRx Health to acquire EMJX in all-stock deal valued at ~$55M; Eric Jackson to become CEO and Chairman","event_type":"m_and_a","confidence":"high","bullets":["Aggregate purchase price ~$55M payable in stock; transaction unanimously approved by SRx Health Board.","Closing expected Q1 2026; subject to SRx shareholder approval, SEC filings, listing approval, and other conditions.","Upon closing, Eric M. Jackson (EMJX founder/CEO) to serve as CEO and Chairman of combined company; combined entity to operate under EMJX name.","EMJX is a Gen2 digital-asset treasury platform using quantitative models and AI for multi-asset risk management; target is to reduce reliance on equity dilution.","The IP asset includes an AI algorithm designed to outperform Bitcoin and Ethereum based on trading volatility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120607,"accession_number":"0001493152-25-024432","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"SRx Health Solutions increases authorized common stock from 200M to 5B shares","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 200M to 5B via Certificate of Amendment filed Nov 19, 2025.","Stockholders approved the amendment on Oct 8, 2025; effective upon filing with Delaware Secretary of State.","Number of authorized preferred shares remains unchanged at 4 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120606,"accession_number":"0001493152-25-021463","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"SRx Health Solutions appoints Sammy Dorf to Board of Directors","event_type":"leadership","confidence":"high","bullets":["Sammy Dorf appointed as director effective November 10, 2025.","Dorf is Executive Chairman of Flora Growth Corp. (NASDAQ: FLGC) and co-founded Verano Holdings.","He raised over $300M in capital and secured 25+ licenses across 14 states.","Brings expertise in cannabis, crypto, and alternative asset strategy.","Appointment adds regulatory and growth experience to the board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120605,"accession_number":"0001493152-25-020457","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["1.01","2.03","3.02","5.02","5.03","9.01"],"status":"ready","headline":"SRx Health raises $15.23M in first closing of Series A preferred offering; secures up to $1B equity commitment","event_type":"other_material","confidence":"high","bullets":["First closing of private placement: 19,035 Series A Preferred shares and 54.5M warrants for $15.23M; additional closings at investor option up to $30.46M total.","Amendment to July 2025 Purchase Agreement increased total commitment from $50M to $1B; issued $20M convertible promissory note in connection.","Series A Preferred conversion price fixed at $0.6109; warrants exercisable at $0.6109; company seeks stockholder approval to raise authorized common from 200M to 5B shares.","Directors Lionel F. Conacher and David Allen White resigned Oct 31, 2025; committees reconstituted with Michael Young, Simon Conway and Joshua A. Epstein."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120604,"accession_number":"0001493152-25-018441","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"SRx Health receives NYSE American deficiency notice for stockholders' equity below $4M","event_type":"regulatory","confidence":"high","bullets":["Received NYSE American notice on Oct 14, 2025 for non-compliance with Section 1003(a)(ii) due to stockholders' equity below $4M and net losses.","Company must submit compliance plan by Nov 13, 2025 and cure deficiency by July 14, 2026.","No immediate delisting; common stock continues trading on NYSE American under symbol SRXH.","Company is actively developing measures to regain compliance within the cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120603,"accession_number":"0001493152-25-017575","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SRx Health stockholders approve 25x share increase and up to 85:1 reverse split","event_type":"other_material","confidence":"high","bullets":["Authorized shares increased from 200M to 5B; additional reverse split range 15:1 to 85:1 approved.","Issuance above 19.99% outstanding authorized under ELOC Purchase Agreement and July 2025 SPA.","Bylaw quorum lowered from majority to one-third of outstanding shares.","Written consent holders with 51.20% voting power approved all matters; no opposition.","Additional reverse split must occur by March 31, 2026 at Board's discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120602,"accession_number":"0001493152-25-017043","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"SRx Health Solutions appoints Joshua Epstein to board and compensation committee","event_type":"leadership","confidence":"high","bullets":["Joshua A. Epstein appointed to SRx Health Board of Directors, effective October 1, 2025.","He brings over 20 years of experience in energy, healthcare, cannabis, and technology sectors.","Currently head of Corporate Development at Lisbon Valley Mining Co.; former CEO of Socati Corp.","Epstein will also serve on the Board's Compensation Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137211,"accession_number":"0001493152-25-014303","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["4.01","8.01","9.01"],"status":"ready","headline":"SRx Health Solutions dismisses auditor, enters CCAA asset sales; identifies $1.8M revenue error","event_type":"other_material","confidence":"high","bullets":["Dismissed CBIZ CPAs, engaged Davidson & Company as auditor for FY2025 ending Sept 30.","Identified $1.8M revenue overstatement in FY2024; will revise, not restate, statements.","Prior auditors flagged going-concern doubts and multiple material weaknesses (IT controls, revenue recognition).","SRx Canada subsidiary in CCAA creditor protection; majority of assets sold via court-approved transactions.","Material weakness expected related to revenue recognition; additional control deficiencies reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137210,"accession_number":"0001641172-25-023868","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"SRx Health cancels 18.8M shares (60% of total) via settlement; director resigns","event_type":"other_material","confidence":"high","bullets":["18.8M shares forfeited and canceled, representing ~60% of total outstanding Common Stock and Exchangeable Shares.","Settlement releases founders from certain claims; SRx Canada subsidiary is under CCAA creditor proceedings.","Board member Adesh Vora resigned effective August 13, 2025, citing SRx Canada's CCAA proceedings.","Company intends to explore legal remedies against former officers not party to the settlement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137209,"accession_number":"0001641172-25-023256","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"SRx Health Solutions' Canadian subsidiary enters CCAA restructuring; DIP financing obtained","event_type":"other_material","confidence":"high","bullets":["SRx Canada obtained Initial Order under CCAA from Ontario Superior Court, including a stay of proceedings.","DIP financing secured of up to $1,750,000 (includes insider participation) for working capital and restructuring.","Court approved a sale process that may result in sale of all or substantially all of SRx Canada's assets.","Company states no impact on U.S. parent or Halo subsidiary; no U.S. bankruptcy filing expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137208,"accession_number":"0001641172-25-021348","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"SRx Health stockholders approve reverse stock split at ratio up to 60:1 before March 2026","event_type":"other_material","confidence":"high","bullets":["Stockholders holding 51.5% of voting power (17,088,904 shares) approved Reverse Stock Split via written consent on July 23, 2025.","Board authorized to implement split at ratio between 15-to-1 and 60-to-1, at any time before March 31, 2026.","Exact split ratio and timing remain at Board's sole discretion; no further stockholder vote required.","No votes against, abstaining, or broker non-votes; approval by written consent without a meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137207,"accession_number":"0001641172-25-019864","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"SRx Health appoints Kent Cunningham CEO; Adesh Vora becomes Executive Chairman; CFO gets raise","event_type":"leadership","confidence":"high","bullets":["Adesh Vora resigned as CEO July 8; replaced by Kent Cunningham, previously President.","Cunningham receives $444K base salary, 70% bonus target, and $3M equity award upon profitability.","CFO Carolina Martinez salary increased to $325K retroactively, plus $150K one-time bonus, with clawback within 90 days.","Vora appointed Executive Chairman of the board effective immediately (per press release)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137206,"accession_number":"0001641172-25-019652","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"SRx Health closes $7.3M convertible note financing and secures $50M equity line of credit","event_type":"other_material","confidence":"high","bullets":["Closed $7.3M convertible note financing led by insiders and existing investors; notes bear 8% interest, mature July 2027.","Notes convertible at $0.6274 per share; warrants issued to purchase 21,338,062 shares at $0.6274, exercisable for 3 years.","Secured $50M equity line of credit (ELOC) with a lead investor; $1M in commitment shares issued at a discount to market.","Proceeds to support U.S. M&A pipeline, Canadian specialty pharma expansion, and working capital for growth initiatives.","Company granted security interest in substantially all U.S. business assets as collateral for the note financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137205,"accession_number":"0001641172-25-018789","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K/A","filed_at":"2025-07-11T23:59:59+00:00","items":["9.01","1.01","2.01","5.01","5.02","5.03","8.01"],"status":"ready","headline":"SRx Health acquires SRx Canada; FY2024 net loss C$59.4M, goodwill impairment C$26.9M, going concern doubt","event_type":"other_material","confidence":"high","bullets":["SRx Canada revenue C$200.5M for year ended Sep 30, 2024, net loss C$59.4M vs loss C$15.1M prior year.","Goodwill impairment C$26.9M and intangibles impairment C$2.1M recorded in FY2024.","Auditor's report includes material uncertainty about going concern due to net capital deficiency of C$72.0M.","As of Sep 30, 2024, total liabilities C$117.6M exceed total assets C$45.6M.","Pro forma combined financials filed; business combination closed Apr 24, 2025, with SRx Canada as surviving entity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154503,"accession_number":"0001641172-25-015024","cik":1471727,"company_name":"SRx Health Solutions, Inc.","ticker":"SRXH","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"SRx Health Solutions appoints new CEO, President, Chairman and CFO","event_type":"leadership","confidence":"high","bullets":["Davender Sohi resigned as President effective June 10, 2025; no dispute cited.","Kent Cunningham appointed President, Adesh Vora appointed CEO, and Lionel Conacher appointed Chairman, effective June 11, 2025.","Nina Martinez appointed Chief Financial Officer, effective June 11, 2025.","All appointees held prior officer/director roles; base compensation unchanged.","Company refocuses on chronic disease, infusion services, clinical trials, and patient support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.73,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}